Clinical Trials Search Results

Page 1 of 1 | Results 1 - 4 of 4

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after...
Breast Cancer
Samir Undevia, MD

Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

Accepting Participants

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence

We are doing this study to learn more about an experimental drug called camizestrant. Experimental means it hasn’t been fully tested and it is not...
Breast Cancer
Amaryllis Gil, MD

Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

Accepting Participants

Testing the usual treatment of radiation therapy and hormonal therapy to hormonal therapy alone for low-risk, early stage breast cancer

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive...
Breast Cancer
Sania Raza, MD

Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

Accepting Participants

Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in high risk HER2-positive patients with residual invasive breast cancer following neoadjuvant therapy

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher...
Breast Cancer
Joseph Kash, MD

Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

Accepting Participants
Page 1 of 1 | Results 1 - 4 of 4